EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping

John Hallick, Anne-Marie Baird, Gerald Falchook, Xiuning Le, David Hong, Santiago Viteri, Jo Raskin, Niels Reinmuth, Soetkin Vlassak, Mihaela Militaru, Paul K Paik

Future Oncology · 2023

DOI: 10.2217/fon-2022-1035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von John Hallick und 10 weiteren Autor:innen. Beteiligte Einrichtung: Patient author, MET Crusaders, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EMD Serono Research & Development Institute, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WHAT IS THIS SUMMARY ABOUT?: This plain language summary provides an overview of two of the main clinical studies that led to tepotinib's approval, the phase I first-in-human study and the phase II VISION study. WHAT IS TEPOTINIB?: Tepotinib is a targeted anti-cancer treatment taken orally (by mouth). It is available in many countries for people with advanced or metastatic non-small cell lung cancer (NSCLC), where the tumor contains a genetic mutation (alteration) called 'MET exon 14 skipping'. Tumor cells rely on this mutation to grow and survive, so targeted blocking of the effect of this mutation is an important treatment approach. MET exon 14 skipping occurs in approximately 3-4% of people with NSCLC. These people are usually of older age. This subtype of NSCLC is associated with poor outcomes. Before treatments that specifically target this MET mutation were developed, only general treatments such as chemotherapy were available for this type of cancer. Because chemotherapy attacks all rapidly dividing cells in a person's body and is administered intravenously (through a vein), it can often cause unwanted side effects. Cancer cells grow and divide rapidly because of defects, often involving proteins called 'tyrosine kinases'. Specific tyrosine kinase inhibitors (TKIs) were therefore developed to slow or stop cancer growth by targeting these proteins. Tepotinib is a MET TKI. This means that it blocks the activity of the MET pathway that is overactive in MET exon 14 skipping NSCLC. Doing this, may slow down cancer growth. WHAT WERE THE RESULTS FROM THE CLINICAL STUDIES OF TEPOTINIB?: In the studies summarized here, people with MET exon 14 skipping NSCLC who took tepotinib had their tumor growth stopped or their tumor shrunk for a period of time, and they mostly experienced side effects that they could tolerate. Clinical Trial Registration: NCT01014936 (tepotinib first-in-human), NCT02864992 (VISION), NCT03940703 (INSIGHT 2) (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansExonsMutationProtein Kinase InhibitorsProto-Oncogene Proteins c-metPiperidinesPyridazinesPyrimidines

Stichwörter der Autor:innen

MET exon skippingNSCLClay summarynon small cell lung cancerplain language summarytargeted therapytepotinibtyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-mettepotinibPiperidinesPyridazinesPyrimidines

Autor:innen und Institutionen

  • Patient author, MET Crusaders, USA.
  • Trinity Translational Medicine Institute, Trinity College, University of Dublin, Ireland.
  • Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
  • Department of Thoracic Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • UOMI Cancer Center, Clínica Mi NovAliança, Lleida, Spain.

Förderung

  • EMD Serono Research & Development Institute, Inc.

Zitieren

APA

Hallick, J., Baird, A. M., Falchook, G., Le, X., Hong, D., Viteri, S., Raskin, J., Reinmuth, N., Vlassak, S., Militaru, M., & Paik, P. K. (2023). Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping. Future Oncology. https://doi.org/10.2217/fon-2022-1035

Vancouver

Hallick J, Baird AM, Falchook G, Le X, Hong D, Viteri S, et al. Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping. Future Oncology. 2023. doi:10.2217/fon-2022-1035

BibTeX
@article{Hallick2023,
  author = {Hallick, John and Baird, Anne-Marie and Falchook, Gerald and Le, Xiuning and Hong, David and Viteri, Santiago and Raskin, Jo and Reinmuth, Niels and Vlassak, Soetkin and Militaru, Mihaela and Paik, Paul K},
  title = {Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2022-1035}
}
Kostenlos starten →